The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 23, 2007
Filed:
Dec. 02, 2003
John S. Babcook, Vancouver, CA;
Jaspal S. Kang, Surrey, CA;
Orit Foord, Foster-City, CA (US);
Larry Green, San Francisco, CA (US);
Xiao Feng, Union City, CA (US);
Scott Klakamp, Fremont, CA (US);
Mary Haak-frendscho, Newark, CA (US);
Palaniswami Rathanaswami, Vancouver, CA;
Craig Pigott, Cambridge, GB;
Meina Liang, Danville, CA (US);
Yen-wah Lee, Newark, CA (US);
Kathy Manchulenko, Port Coquitlam, CA;
Raffaella Faggioni, Pleasanton, CA (US);
Giorgio Senaldi, Dublin, CA (US);
Qiaojuan Jane Su, San Jose, CA (US);
John S. Babcook, Vancouver, CA;
Jaspal S. Kang, Surrey, CA;
Orit Foord, Foster-City, CA (US);
Larry Green, San Francisco, CA (US);
Xiao Feng, Union City, CA (US);
Scott Klakamp, Fremont, CA (US);
Mary Haak-Frendscho, Newark, CA (US);
Palaniswami Rathanaswami, Vancouver, CA;
Craig Pigott, Cambridge, GB;
Meina Liang, Danville, CA (US);
Yen-Wah Lee, Newark, CA (US);
Kathy Manchulenko, Port Coquitlam, CA;
Raffaella Faggioni, Pleasanton, CA (US);
Giorgio Senaldi, Dublin, CA (US);
Qiaojuan Jane Su, San Jose, CA (US);
Amgen Fremont, Inc., Fremont, CA (US);
Abstract
Antibodies directed to the antigen TNFα and uses of such antibodies. In particular, fully human monoclonal antibodies directed to the antigen TNFα. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.